Hormone Receptor-Positive Breast Cancer Treatment in India
- Top Accredited Hospitals
- Global Medical Standards
- Cutting-Edge Technology
- Proven Treatment Options
- High Success Rate
- Trusted by Millions
What is a Hormone Receptor-Positive Breast Cancer?
Hormone receptor-positive breast cancer is a type of breast cancer in which cancer cells have receptors for estrogen (ER), progesterone (PR), or both hormones. These hormones can stimulate the growth of hormone receptor-positive cancer cells.
Hormone receptor-positive breast cancer can occur at different stages, and treatment depends on the tumour size, lymph-node involvement, grade, HER2 status, menopausal status, genomic characteristics, and overall health.
What is the Importance of Timely Treatment?
Timely diagnosis and treatment of hormone receptor-positive breast cancer can help control tumour growth and reduce the risk of recurrence or spread to other parts of the body. Depending on the stage and biological features, treatment may also include surgery, radiotherapy, chemotherapy, targeted therapy, or immunotherapy. Long-term follow-up is important because hormone receptor-positive breast cancer can recur even several years after the initial treatment.
What are the Common Symptoms of Hormone Receptor-Positive Breast Cancer?
- A new lump or thickening in the breast
- A change in breast size or shape
- Changes in the skin of the breast
- Nipple inversion or other nipple changes
- Unusual nipple discharge, including bloody discharge
- Persistent breast or nipple pain
- Swelling or a lump in the underarm area
- Changes in the appearance or texture of the breast
Causes and Risk Factors of Hormone Receptor-Positive Breast Cancer
Causes
- Hormone receptor-positive breast cancer develops when genetic and molecular changes cause breast cells to grow and divide abnormally.
- The exact cause is usually not identifiable in an individual patient. Hormonal exposure, inherited genetic susceptibility, age-related cellular changes, and other biological factors may contribute to risk.
Risk Factors
- Increasing age
- Family history of breast or ovarian cancer
- Inherited genetic mutations such as BRCA1 or BRCA2
- Longer lifetime exposure to estrogen
- Early onset of menstruation or later menopause
- Having no pregnancies or having a first pregnancy at a later age
- Use of certain menopausal hormone therapies
- Alcohol consumption
- Overweight or obesity after menopause
- Previous radiation exposure to the chest at a young age
- Certain breast conditions associated with increased cancer risk
Latest Research and Technologies in the Treatment of Hormone Receptor-Positive Breast Cancer in India
- Treatment of hormone receptor-positive breast cancer is increasingly guided by tumour biology, genomic characteristics, and molecular biomarkers. Endocrine therapy remains a major treatment approach, while CDK4/6 inhibitors have expanded treatment options for selected patients. In advanced or metastatic disease, molecular testing may identify alterations. Newer endocrine approaches, including oral selective estrogen receptor degraders, are also expanding options for selected patients with endocrine-resistant disease. Genomic assays may help estimate recurrence risk and inform chemotherapy decisions in selected early-stage, hormone receptor-positive and HER2-negative cancers.
Treatment options for Hormone Receptor-Positive Breast Cancer
Mastectomy : A mastectomy is a surgical procedure to remove all or part of a breast, most commonly used to treat or prevent breast cancer.
Cost Start From 4250Explore Options
Radiotherapy: Radiation therapy is commonly used after breast-conserving surgery and may be recommended after mastectomy or lymph-node surgery in selected patients.
Chemotherapy : Chemotherapy may be recommended when the risk of recurrence is sufficiently high or when tumour and genomic characteristics suggest a potential benefit.
Cost Start From 300Explore Options
CDK4/6 inhibitors: Medicines may be used with endocrine therapy in selected early-stage or advanced hormone receptor-positive breast cancers.
Targeted therapy : Targeted medicines may be considered when specific molecular alterations or HER2 expression are identified.
Cost Start From 1000Explore Options
Immunotherapy : Immunotherapy is used in selected breast cancer settings based on tumour subtype and biomarkers; it is not required for all hormone receptor-positive cancers.
Cost Start From 1500Explore Options
Hormone therapy : It is also known as endocrine therapy, is the primary treatment for Hormone Receptor-Positive (HR+) breast cancer. Hormone therapy does not replace standard chemotherapy or surgery; rather, it acts as a full-body (systemic) treatment to stop the body's natural hormones from feeding remaining cancer cells.
Cost Start From 1500Explore Options
- Clinical assessment:
- Core needle biopsy: Provides tissue for confirming breast cancer.
- Histopathology: Determines the cancer type, grade, and other microscopic characteristics.
- ER and PR testing: Determines whether the tumour is hormone receptor-positive.
- HER2 testing: Determines whether HER2-targeted treatment may be appropriate.
- Ki-67: May be assessed in selected settings as a marker of tumour cell proliferation.
- Genomic assays: Tests such as Oncotype DX or other validated assays may help estimate recurrence risk and potential chemotherapy benefit in selected early-stage HR-positive/HER2-negative cancers.
- Genetic testing: BRCA1, BRCA2, and other hereditary cancer genes may be evaluated in patients who meet appropriate clinical criteria.
- Imaging Tests:
- Mammography: Helps identify suspicious breast changes and is commonly used for diagnosis and screening.
- Breast ultrasound: Helps evaluate breast lumps and distinguish solid from cystic lesions.
- Breast MRI: May be recommended for selected patients, particularly when additional assessment is needed.
- CT or PET/CT: May be used for staging in selected patients with locally advanced or metastatic disease.
- Bone imaging: Consider a bone scan or other imaging when bone involvement is suspected.
- Additional imaging: Imaging of specific organs may be performed when symptoms or clinical findings suggest possible metastatic disease.
MediRehab (a chain of Rehab centres, part of MediGence) provides comprehensive rehabilitation services designed to support Hormone Receptor-Positive Breast Cancer patients in India. These services include:
- Post-surgical rehabilitation: Exercises to restore shoulder movement, arm strength, and upper-body function after breast or lymph-node surgery.
- Lymphedema management: Assessment, exercise, compression strategies, and specialised therapy when swelling develops in the arm or breast.
- Physical activity: Gradual aerobic and resistance exercise can help improve strength, mobility, cardiovascular health, and fatigue.
- Bone health support: Patients receiving aromatase inhibitors or other treatments that affect bone health may require exercise, nutritional guidance, and monitoring.
- Fatigue management: Activity planning, sleep support, nutrition, and energy-conservation strategies can help manage treatment-related fatigue.
- Psychological support: Counselling and supportive-care services can help patients manage anxiety, emotional stress, body-image concerns, and treatment-related challenges.
- Medicines for hormone receptor-positive breast cancer are selected according to the stage, menopausal status, HER2 status, molecular profile, previous treatment, and treatment goals. For selected patients with advanced or high-risk disease, endocrine therapy may be combined with CDK4/6 inhibitors. Consider molecularly targeted medicines when specific alterations. Oral estrogen-receptor-directed therapies may also be used in selected patients with endocrine-resistant disease. Supportive medicines may be prescribed to manage treatment-related symptoms, protect bone health, control nausea or pain, and address other side effects.
Instantly Connect with our Specialists
Hospitals for Hormone Receptor-Positive Breast Cancer in India
Fortis Memorial Research Institute
Gurgaon, India
Fortis Healthcare Limited stands as one of India's largest integrated healthcare providers, managing 33 hospitals across 11 states and operating more than 5,700 beds and 400 diagnostic labs. Four of our hospitals are accredited by JCI and 26 by NABH. With a workforce of over 12,500 healthcare professionals, we combine clinical excellence, a patient-focused approach, and innovation to provide high-quality, affordable, and compassionate healthcare to patients in India.
Max Super Speciality Hospital, Saket
Delhi, India
Max Smart Super Speciality Hospital, Saket, is a 250-bed tertiary care hospital awarded NABH accreditation, which provides advanced medical care in various specialities such as Cardiac Sciences, Orthopaedics, Neurology, Urology, Kidney Transplant, Paediatrics, and Obstetrics & Gynaecology. The hospital provides quality, safe, integrated, and patient-centric medical care using modular OTs, ICUs, Cath Labs, CT, MRI and Dialysis units.
Manipal Hospital, Hebbal
Bangalore, India
Manipal Hospitals, a group of Manipal Education Medical Group, is India’s leading multi-speciality network, comprising over 650 beds. Dedicated to clinical excellence, patient-centric care and ethical practices, it provides sophisticated diagnostics, surgery and home care services to both domestic and international patients, while also improving access to affordable healthcare for underprivileged communities.
Our Services to better your experience
Opinion & Option
We submit the most accurate opinion and options from one or more countries for your review
Consult Privately
Consult with a certified specialist privately on our telemedicine platform even before you decide to travel
Logistics
We handle flights, visas, transfers, and accommodation—so you can focus on your health.
Recovery
Our In-house rehabilitation service packages to better your recovery and treatment outcome
Why Choose India for Hormone Receptor-Positive Breast Cancer Treatment?
- Experienced breast cancer specialists: Breast surgeons, medical oncologists, radiation oncologists, pathologists, radiologists, and other specialists can contribute to treatment planning.
- Advanced diagnostic facilities: Mammography, ultrasound, breast MRI, biopsy, pathology, hormone receptor testing, HER2 testing, genetic testing, and selected genomic assays can support personalised treatment planning.
- Modern treatment options: Eligible patients may have access to breast-conserving surgery, mastectomy, advanced radiotherapy, endocrine therapy, chemotherapy, CDK4/6 inhibitors, targeted therapies, and other systemic treatments.
- Multidisciplinary cancer care: Treatment planning may involve breast specialists, oncologists, pathologists, radiologists, genetic counsellors, nutritionists, physiotherapists, and rehabilitation professionals.
- International patient support: Many major hospitals provide dedicated international patient services, including medical coordination, documentation, accommodation, travel assistance, and follow-up planning.